NASD · Basic Materials · Specialty Chemicals · Malaysia
BioNexus Gene Lab Corp is a micro cap company (market value under $300 million) in the Specialty Chemicals industry.
BioNexus Gene Lab Corp operates through two subsidiaries in Malaysia: Chemrex distributes chemical raw materials for industrial applications across Southeast Asia, while MRNA Scientific provides blood-based genomic screening services for disease risk assessment. The company recently acquired exclusive rights to the VitaGuard minimal residual disease platform for the ASEAN region.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the BioNexus Gene Lab Corp stock.
Undervalued: intrinsic value $1.65 per share, market price $0.92, margin of safety 44.1% (as of 2026-10-30).
Its liquidation floor, current assets minus every liability, values the shares at $1.65; the price of $0.92 is 44% below that value.
Leak Score: 63/100 on 8 of 12 signals (Faint Leak).
All 62 Specialty Chemicals stocks
BGLC is undervalued (as of the 2026-10-30 close). Its liquidation floor, current assets minus every liability, values the shares at $1.65; the price of $0.92 is 44% below that value.
$1.65 per share (as of the 2026-10-30 close), against a market price of $0.92. That is a margin of safety of 44.1%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.
63 out of 100, which we rate "Faint Leak", on 8 of 12 value investing signals.